Subscribe to RSS
Rivaroxaban and Apixaban Anti-Xa Measurements: Impact of Plasma Storage for 7 Days at Room Temperature
09 May 2018
24 May 2018
30 June 2018 (online)
The advent of direct oral anticoagulants (DOACs) is a major breakthrough in the management of patients with venous thromboembolic diseases and atrial fibrillation. Clinical trials with DOACs have been performed without laboratory assessment, owing to their predictable anticoagulant response and wide therapeutic index. However, there are several circumstances in which assessment of DOAC effect may be desirable.    Besides life-threatening situations in which an assay with rapid turnaround time may impact patient care, in settings such as extreme body weight, renal function impairment, gastrointestinal malabsorption, drug interactions or suspicion of overdose, a non-urgent measurement of DOAC may be needed.    Only specific tests are deemed reliable to accurately measure DOAC concentrations but they are not widely available on a 24h/7d basis. Therefore, in non-urgent situations, samples may be transferred to a central laboratory and testing may be delayed for cost and workflow efficiency. To ensure precise and accurate measurements, both inappropriate storage conditions and the expiration of a time-limit before assaying the sample should be avoided. Nevertheless, precise data about storage conditions and maximum time before assaying the sample are lacking.
The aim of this study, performed in two university hospitals using different techniques, was to test whether rivaroxaban and apixaban plasmatic measurements are stable after being stored at room temperature up to 7 days after sampling.
E. Boissier: conception and design, analysis and interpretation of the data, drafting and revision of the manuscript. S. Genebrier: data collection and revision of the manuscript. K. Lakhal: analysis and interpretation of the data and revision of the manuscript. F. Nedelec-Gac: data collection and revision of the manuscript. C. Ternisien: interpretation of the data and revision of the manuscript. I. Gouin-Thibault: conception and design, analysis and interpretation of the data, drafting and revision of the manuscript.
- 1 Baglin T, Hillarp A, Tripodi A, Elalamy I, Buller H, Ageno W. Measuring oral direct inhibitors (ODIs) of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2013; 11: 756-760
- 2 Gosselin RC, Adcock DM. The laboratory's 2015 perspective on direct oral anticoagulant testing. J Thromb Haemost 2016; 14 (05) 886-893
- 3 Samuelson BT, Cuker A, Siegal DM, Crowther M, Garcia DA. Laboratory assessment of the anticoagulant activity of direct oral anticoagulants: a systematic review. Chest 2017; 151 (01) 127-138
- 4 Martin K, Beyer-Westendorf J, Davidson BL, Huisman MV, Sandset PM, Moll S. Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. J Thromb Haemost 2016; 14 (06) 1308-1313
- 5 McGrail R, Revsholm J, Nissen PH, Grove EL, Hvas AM. Stability of direct oral anticoagulants in whole blood and plasma from patients in steady state treatment. Thromb Res 2016; 148: 107-110
- 6 Schmitz EMH, Boonen K, van den Heuvel DJA. , et al. Determination of dabigatran, rivaroxaban and apixaban by ultra-performance liquid chromatography - tandem mass spectrometry (UPLC-MS/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulants. J Thromb Haemost 2014; 12 (10) 1636-1646
- 7 Albaladejo P, Bonhomme F, Blais N. , et al; French Working Group on Perioperative Hemostasis (GIHP). Management of direct oral anticoagulants in patients undergoing elective surgeries and invasive procedures: Updated guidelines from the French Working Group on Perioperative Hemostasis (GIHP) - September 2015. Anaesth Crit Care Pain Med 2017; 36 (01) 73-76
- 8 Gouin-Thibault I, Freyburger G, de Maistre E. , et al; GFHT study group on DOAC. Evaluation of dabigatran, rivaroxaban and apixaban target-specific assays in a multicenter French study. Thromb Res 2017; 158: 126-133